Compare Heron Therapeutics Inc (HRTX) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $25.84 (market cap $115.44M). The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is the larger of the two by market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| HRTX | KOLD | |
|---|---|---|
Market Cap | $74.04M | $115.44M |
Volume | 3,668,095 | 6,626,046 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.49 | $49.39 |
52-Week Low | $0.27 | $13.58 |
Typical Hold Time | 35 Days | 10 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
KOLD is trading at $24.84, down 5.8% over the past 24 hours amid bearish technical signals. The stock faces strong selling pressure with moving averages indicating a bearish trend and oscillators in neutral territory. Recent news highlights natural gas market volatility driven by record production levels and geopolitical tensions in the Middle East affecting energy commodities.
The outlook remains challenging with technical indicators pointing to continued downward pressure. Investment opportunities may emerge if the stock finds support near current levels, but risks include ongoing natural gas price volatility and geopolitical uncertainties. The bearish technical setup suggests cautious positioning is warranted until clearer fundamental catalysts emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
